Compare Cassava Sciences Inc (FLNA) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ING Groep NV — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while ING Groep NV trades at $33.37 (market cap $93.76B). The key difference: ING Groep NV is far larger — about 2379.7× Cassava Sciences Inc's market cap, and ING Groep NV pays a 3.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and ING Groep NV for 94 Days on average.
| FLNA | ING | |
|---|---|---|
Market Cap | $39.40M | $93.76B |
Volume | 759,018 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $4.64 | $37.27 |
52-Week Low | $0.68 | $23.66 |
Typical Hold Time | 37 Days | 94 Days |
Enterprise Value | -$43.28M | $236.48B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
ING trades at $33.43, down 1.44% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with revenue growth and raised 2027 ROE targets above 16%. Valuation metrics show a P/E of 12.86 and P/B of 1.68, while analyst consensus remains strongly positive with 64.7% buy ratings.
ING presents a compelling investment case with solid profitability (28.3% net margin) and consistent earnings outperformance, though negative cash flow trends and regulatory challenges in Australia warrant caution. The stock's current technical weakness may offer entry opportunities for long-term investors attracted by the company's growth trajectory and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
